6 key clinical trial trends that we should embrace and build on
Biotech Voices is a collection of exclusive opinion editorials from some of the leading voices in biopharma on the biggest industry questions today. Think you have a voice that should be heard? Reach out to Amber Tong.
When penicillin was discovered in 1928 by Alexander Fleming, the average clinical trial time was 12 years. In 2021, the average industry trial time is 10 years, an improvement of only 2 years. In almost a century, there have been no advancements that have delivered a substantial change to how clinical trials are conducted.
While the Covid-19 pandemic itself had a devastating impact on trials around the world, the disruption it caused also carries with it the chance for innovation. The urgency and acceleration to adopt new ways of working caused by the pandemic is also an opportunity. By maintaining the innovation mindset that initially came from necessity, the industry can drive durable, sustainable innovation with the potential to transform the clinical development model. Here are 6 key trends that we should embrace and build on moving forward.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.